盐酸阿扎司琼对肝肿瘤患者TACE术后止吐疗效观察

目的:评估盐酸阿扎司琼对肝肿瘤患者TACE术后恶心呕吐的预防作用。方法:62例病人(其中原发性肝癌33例,转移性肝癌29例),共行78例次TACE治疗,被随机地分入A、B两组,A组(盐酸阿扎司琼组)32例,共42例次,在动脉化疗栓塞术前10分钟内静脉注射盐酸阿扎司琼10mg,术后3-5小时再静注一次。B组(对照组)30例,共36例次,在动脉灌注化疗药前10分钟内静脉注射甲氧氯普胺片(胃复安)10mg,术后3-5小时再静注胃复安10mg。并观察TACE术后A、B组的止吐效果。结果:A组的止吐完全缓解率(CR)和有效率(CR+PR)分别为81.0％和99.7％,明显地高于B组(11.1％和66.7％)(P<0.01)。并且没有发现与阿扎司琼有关的不良反应。结论:盐酸阿扎司琼高效、安全,是一种能预防肝TACE术后所致恶心呕吐反应的较为理想的药物。

Evaluation on the antiemetic effect of azasetron hydrochloride in patients with liver neoplasm after transcatheter arterial chemoembolization

Purpose: To evaluate the antiemetic effect of azasetron hydrochloride in patients with liver neoplasm after transcatheter arterial chemoembolization. Methods: 62 patients (33 with primary hepatocellular carcinoma and 29 with hepatic metastasis), who underwent transcatheter arterial chemoembolization( TACE) therapy 78 times in all, were allocated into the azasetron group( administration of azasetron hydrochloride) and the control group( administration of metoclopramide) randomly. The inhibitory effects on nausea and vomiting were observed in the two groups respectively. Results: The antiemetic CR ratio and the response rate( CR + PR) in the azasetron group was 81.0% and 99. 7%, respectively. These results were statistically higher than those in the control group( P < 0. 01). No side effects and complications related to administration of azasetron hydrochloride were observed. Conclusions: Azasetron hydrochloride was considered to be a highly effective and safe antiemetic drug in patients with liver neoplasm after TACE therapy.